Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: Tenchusatsu who wrote (1501262)	11/13/2024 2:36:10 PM
From: i-node	1 Recommendation Recommended By longz Read Replies (2) \| Respond to of 1570343

>> Meanwhile, remdesivir (from Gilead Sciences here in South San Francisco) itself was a repurposed drug. Yes, and it was crap and sold for $3,000 for a course of treatment. Other treatments were arguably quite a bit more effective and far less expensive. There are people out there looking for opportunities to make a ton of money. But few are interested in true repurposing. While numbers are hard to come by, a rough estimate of the total spending on drug repurposing -- expenditures from all sources in the US, ranges from $300M to 1.5B, with a moderate estimate of $750M. Often, there are excellent clues as to viability that go without follow-up. It is pathetic. I appreciate what Ramaswamy was trying to do -- and he did have allegedly some success -- we need to be focusing on incentives turn examine alternatives that might produce significant results for little money. Yes, I'm a true believer. But every day, I take Curcumen/Phytosome for pain, and if I don't take it my pain levels increase materially (I also take three other drugs daily for the same pain). Millions besides me do the same. But because I don't go to a fucking drugstore to get it, no one researches it. Same with other so-called "supplements" -- drugs that have been used for centuries to treat various problems. The pharma racket is astounding. What is happening today with Medicare drug plans is a train wreck -- government has now limited the annual out of pocket expenditure for old people's meds to $2,000 -- that is a great for me, since my wife is on one that would cost $22K/year, and last year we scrambled to find more affordable workarounds. It is a big challenge, but the law surrounding drug patents and costs must be addressed, and that includes finding cheaper alternatives and funding studies of existing drugs/molecules that show promise for speeding up treatments for the major consumers of health care dollars in the US. Given the waste in other areas there is no reason we can't be doing this while cutting overall costs. If you look at the cost of Alz disease and other aging problems, there is a lot of money to work with.